Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

In this news, Revionics launches alpha version of its multi-agent AI pricing system at Google Cloud Next 2025, showcasing ...

The HYPE token rose to a high of $14.95 on Friday, up by 60% from its lowest point this month as the Hyperliquid volume rises ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The latest advances and the future of Google Cloud Platform and cloud computing in general are on display at Google Cloud ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

Lloyds Banking Group has taken a significant step in its strategic transformation, leveraging the artificial intelligence (AI) and data science capabilities of Google Cloud to transform customer and ...

Vertex Pharmaceuticals is a global biotechnology ... Which Stocks Are Analysts Recommending Now? Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets.